Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exocord
- Development stage
- Preclinical
- Lead developer
- Crioestaminal
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Topical, Subcutaneous, Intradermal, Intraperitoneal, Vaginal, Ophthalmic, Inhalation, Intranasal, Intralesional
01
Overview
Exocord is a regenerative medicine candidate developed by Crioestaminal (Stemlab) that utilizes growth factors and exosomes derived from umbilical cord blood stem cells. The product is designed to facilitate chronic wound healing, particularly in the context of diabetes, by delivering bioactive molecules that promote angiogenesis, cell proliferation, and tissue repair. By using a cell-free approach based on the secretome of stem cells, Exocord aims to provide the therapeutic benefits of cell therapy with improved stability and reduced immunogenicity compared to live cell transplantation. Preclinical research for its primary indications has been completed, positioning the asset for potential clinical advancement in wound care.
- Brand names
- Exocord
02
Targets
TGFBR (TGF-beta receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFR (PDGFR family)
Beyond the preview
Go deeper on Exocord.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exocord.